IP : Diurnal Group plc - Notice of R&D Day

Diurnal Group plc - Notice of R&D Day

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces it will host an R&D Day for analysts and institutional investors on 2 February 2022 at 14:00 GMT (09:00 ET).

The R&D Day will be held in-person at FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD, with the option to attend virtually.

To register to attend in person, or to receive a link to the webcast, please contact [e-mail] .

A recording of the event will be available on Diurnal's website after the event.

For further information, please visit www.diurnal.co.uk or contact:

Diurnal Group plc

[phone]

Martin Whitaker, Chief Executive Officer

Richard Bungay, Chief Financial Officer

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Corporate Broker)

[phone]

Corporate Finance: Freddy Crossley, Emma Earl

Corporate Broking: Rupert Dearden

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

[phone]

Healthcare Investment Banking: Nicholas Moore, Samira Essebiyea

Corporate Broking: Nick Adams

FTI Consulting (Media and Investor Relations)

[phone]

Simon Conway

Victoria Foster Mitchell

Alex Davis

Notes to Editors

About Diurnal Group plc

Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena

For further information about Diurnal, please visit www.diurnal.co.uk